急性胰腺炎积极与适度液体复苏比较
在18个中心开展的随机试验,将急性胰腺炎患者分为目标导向的积极复苏组(乳酸林格液20 ml/kg推注后3 ml/kg/h)与适度复苏组(低血容量者10 ml/kg推注、等容量者不推注,随后均1.5 ml/kg/h),计划样本量744例,首次中期分析纳入249例后因安全性差异提前终止。主要结局(住院期间中度重症或重症胰腺炎)在积极组22.1%、适度组17.3%(校正相对风险1.30,95%CI 0.78~2.18,P=0.32),无显著差异。液体过负荷在积极组20.5%、适度组6.3%(校正相对风险2.85,95%CI 1.36~5.94,P=0.004)。住院中位时间积极组6天(四分位距4~8)、适度组5天(四分位距3~7)。
要点
- 中期分析纳入249例后试验因安全性差异提前终止,积极复苏未降低中度重症或重症胰腺炎发生率(22.1% vs 17.3%,P=0.32)。
- 积极复苏组液体过负荷发生率为20.5%,适度复苏组为6.3%,校正相对风险2.85(95%CI 1.36~5.94,P=0.004)。
- 积极方案为乳酸林格液20 ml/kg推注后3 ml/kg/h;适度方案为低血容量者10 ml/kg推注、等容量者不推注,随后均1.5 ml/kg/h。
- 住院中位时间积极组6天(四分位距4~8),适度组5天(四分位距3~7)。
适用人群与场景
- 在18个中心就诊的急性胰腺炎患者,随机接受目标导向的积极或适度复苏。
处置流程与药物剂量
- 积极复苏组:乳酸林格液20 ml/kg推注,随后3 ml/kg/h。
- 适度复苏组:低血容量患者乳酸林格液10 ml/kg推注,等容量患者不推注,随后全部患者1.5 ml/kg/h。
- 在12、24、48、72小时评估患者,并根据临床状态调整液体复苏。
研究设计与关键结果
- 多中心随机试验,计划样本量744例,首次中期分析在纳入248例后进行;实际中期分析纳入249例,因组间安全性结局差异而提前终止。
- 主要结局(住院期间中度重症或重症胰腺炎)积极复苏组22.1% vs 适度复苏组17.3%,校正相对风险1.30(95%CI 0.78~2.18,P=0.32)。
- 主要安全性结局液体过负荷积极复苏组20.5% vs 适度复苏组6.3%,校正相对风险2.85(95%CI 1.36~5.94,P=0.004)。
- 住院中位时间积极复苏组6天(四分位距4~8)vs 适度复苏组5天(四分位距3~7)。
证据类型、等级与局限
- 证据类型:随机对照试验(中期分析)。
- 试验因安全性结局组间差异提前终止,未达到计划样本量。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在急性胰腺炎患者中,早期积极液体复苏导致液体过负荷发生率更高,而未改善临床结局。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Early aggressive hydration is widely recommended for the management of acute pancreatitis, but evidence for this practice is limited.
METHODS: At 18 centers, we randomly assigned patients who presented with acute pancreatitis to receive goal-directed aggressive or moderate resuscitation with lactated Ringer's solution. Aggressive fluid resuscitation consisted of a bolus of 20 ml per kilogram of body weight, followed by 3 ml per kilogram per hour. Moderate fluid resuscitation consisted of a bolus of 10 ml per kilogram in patients with hypovolemia or no bolus in patients with normovolemia, followed by 1.5 ml per kilogram per hour in all patients in this group. Patients were assessed at 12, 24, 48, and 72 hours, and fluid resuscitation was adjusted according to the patient's clinical status. The primary outcome was the development of moderately severe or severe pancreatitis during the hospitalization. The main safety outcome was fluid overload. The planned sample size was 744, with a first planned interim analysis after the enrollment of 248 patients.
RESULTS: A total of 249 patients were included in the interim analysis. The trial was halted owing to between-group differences in the safety outcomes without a significant difference in the incidence of moderately severe or severe pancreatitis (22.1% in the aggressive-resuscitation group and 17.3% in the moderate-resuscitation group; adjusted relative risk, 1.30; 95% confidence interval [CI], 0.78 to 2.18; P = 0.32). Fluid overload developed in 20.5% of the patients who received aggressive resuscitation and in 6.3% of those who received moderate resuscitation (adjusted relative risk, 2.85; 95% CI, 1.36 to 5.94, P = 0.004). The median duration of hospitalization was 6 days (interquartile range, 4 to 8) in the aggressive-resuscitation group and 5 days (interquartile range, 3 to 7) in the moderate-resuscitation group.
CONCLUSIONS: In this randomized trial involving patients with acute pancreatitis, early aggressive fluid resuscitation resulted in a higher incidence of fluid overload without improvement in clinical outcomes. (Funded by Instituto de Salud Carlos III and others; WATERFALL ClinicalTrials.gov number, NCT04381169.).
参考来源
- de-Madaria E, Buxbaum JL, Maisonneuve P, et al. Aggressive or Moderate Fluid Resuscitation in Acute Pancreatitis. N Engl J Med. 2022. PMID: 36103415. doi:10.1056/NEJMoa2202884
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。